The NewsReport.com- Oct. 19
“Patients with metastatic midgut NET and a high liver tumor load at diagnosis have a poorer prognosis than patients with few liver metastases,,” said Jonathan Strosberg, MD, Associate Professor, Section Head, Neuroendocrine Tumor Program at Moffitt Cancer Center, and Principle Investigator of the NETTER-1 study.
The Weekly Challenger- Oct. 18
The discussion drilled home the importance of inspiring cancer survivors to stay connected and in touch with each other and with Moffitt Cancer Center.
The Oracle – Oct. 17
Llinas would battle the disease for 10 months, never losing his ability to inspire and bring smiles to his fellow students’ faces. He would succumb to complications from the disease on Oct. 11 at Moffitt Cancer Center. He was 23 years old.
Patient Safety and Quality Healthcare – Oct. 17
By Cassandra Vonnes: Our center, the 206-bed Moffitt Cancer Center in Tampa, was still experiencing falls despite having a comprehensive fall prevention program in place.
Healthline – Oct. 16
The new study by Moffitt Cancer Center researchers has concluded that a baseline prostate-specific antigen (PSA) level obtained from African-American men between the ages of 40 and 60 could strongly predict future development of prostate cancer and its most aggressive forms for years after testing.
OncLive – Oct. 16
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma (MCL).
Globe Newswire – Oct. 16
Separately, PanTher also announced that Jason Fleming, MD, chair and senior member of the Department of Gastrointestinal Oncology at Moffit Cancer Center,joined PanTher as a senior clinical advisor. An author on more than 200 publications, Dr. Fleming is a practicing surgical oncologist and active researcher, whose interests include novel surgical methods, biomarkers, and drug development.
Cancer.gov – Oct. 15
The results presented in Toronto come from a longer-term follow-up analysis of the trial. The analysis confirmed the improvement in progression-free survival and showed that patients treated with durvalumab also lived substantially longer overall, reported the study’s lead investigator, Scott Antonia, M.D., Ph.D., of the Moffitt Cancer Center in Florida.
Becker’s Hospital Review – Oct. 15
Dave Summitt, chief information security officer and director of cybersecurity operations at Tampa, Fla.-based Moffitt Cancer Center, discusses the importance of proper risk assessment and security awareness in hospital cybersecurity.
Florida Today – Oct. 15
“We generally see patients as a team,” says Tedeschi’s physician, Dr. Sarah Hoffe, who specializes in gastrointestinal cancers and is section head of radiation oncology at Moffitt and associate professor in the University of South Florida Morsani College of Medicine’s Department of Oncologic Science.
Cure – Oct. 15
With mounting evidence that inflammation is a factor in the development of ovarian cancer, researchers from the Moffitt Cancer Center and the University of Hawaii Cancer Center set out to examine the connection with two studies.
WFLA – Oct. 13
The Lightning Foundation is hosting the 50/50 raffle at every home game this season. The pot is split with half going to one lucky winner. The other half goes to the Lightning Foundation, which is then donated to hundreds of charities throughout the Tampa Bay area. A portion also goes to the Moffitt Cancer Center.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.